- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02478333
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants
July 7, 2016 updated by: Janssen Pharmaceutical K.K.
A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ALS-008176 following oral administration of single ascending dose of ALS-008176 in healthy Japanese adult participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind (test or experiment in which neither the person giving the treatment nor the patient knows which treatment the patient is receiving), placebo-controlled, randomized (study medication assigned to participants by chance) and single-center study of ALS-008176.
The duration of study will be approximately 6 weeks for each participant.
The study consists of 3 parts: Screening Phase (28 days before study commences on Day 1); double-blind Treatment Phase (single oral dose of ALS-008176 or placebo on Day 1 under fasted condition); and Follow up Phase (up to 14 days after study drug administration).
All the eligible participants will be randomly assigned to receive either a single oral dose of ALS-008176 or placebo in each group.
The planned doses will be escalated in a stepwise fashion if the safety and tolerability in the preceding dose is found acceptable.
Participants in Group 1 will receive ALS-008176, 250 milligram (mg) or placebo, Group 2 will receive ALS-008176, 500 mg or placebo and Group 3 will receive ALS-008176, 750 mg or placebo.
Study drug will be administered following a 10-hour overnight fast.
Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment.
Pharmacokinetics of ALS-008176, ALS-008206, ALS-008112, and its metabolite ALS 008144 will be evaluated primarily.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be a Japanese participant whose parents and grandparents are Japanese as determined by the participant's verbal report
- Each participant must sign an Informed Consent Form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study
- Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
A female participant must be either:
- Not of childbearing potential: postmenopausal [greater than (>) 45 years of age with amenorrhea for at least 2 years, or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level >40 International Units (IU)/ liter (L) (to be confirmed at Screening for all postmonopausal women)] OR
- Permanently sterilized (eg, bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or otherwise incapable of becoming pregnant, OR c. If of childbearing potential and heterosexually active, practicing an effective method of birth control before entry and agree to continue to use two effective methods of contraception throughout the study and for at least 30 days after receiving the study drug
- Participant must be a non-smoker for at least one month prior to screening
Exclusion Criteria:
- Participant has a history of current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the Investigator considers should exclude the participant or that could interfere with the interpretation of the study results
- Participant with a past history of heart arrhythmias (extrasystoli, tachycardia at rest), history of risk factors for Torsade de Pointes syndrome (eg, hypokalemia, family history of long QT Syndrome)
- Participant has creatinine clearance of lower than 70 millilitre (mL)/min
- Participant has taken any disallowed therapies as noted in protocol, Pre-study and Concomitant Therapy before the planned study drug
- Participant has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ALS-008176 (250 mg) or Placebo
Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
|
Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
|
EXPERIMENTAL: ALS-008176 (500 mg) or Placebo
Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
|
Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
|
EXPERIMENTAL: ALS-008176 (750 mg) or Placebo
Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
|
Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The Cmax is the maximum observed plasma concentration of ALS 008176, ALS-008206, ALS-008112, and ALS-008144.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Time to Reach the Maximum Plasma Concentration (Tmax) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The Tmax is the time to reach the maximum observed plasma concentration of ALS 008176, ALS-008206, ALS-008112, and ALS-008144.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Time of Last Measurable Plasma Concentration (Tlast) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Time of last measurable (non-below quantification limit [non-BQL]) plasma concentration.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (AUC [0-last]) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The AUC (0-last) is the area under the plasma ALS 008176, ALS-008206, ALS-008112, and ALS-008144 concentration-time curve from time 0 to time of the last observed (non-BQL) quantifiable concentration, calculated by linear-linear trapezoidal summation.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma ALS 008176, ALS-008206, ALS-008112, and ALS-008144 concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed (non-BQL) quantifiable concentration and lambda(z) is elimination rate constant.
Extrapolations of more than 20.00% of the total AUC are reported as approximations.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Percentage of Area Under the Plasma Concentration-Time Curve Obtained by Extrapolation (%AUC[infinity,ex])
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The %AUC[infinity,ex] is calculated by dividing the difference of AUC(0-infinity) and AUC(0-last) by AUC(0-infinity) and then multiplying by 100, (AUC[0-infinity] - AUC[0-last])*100/AUC[0-infinity].
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Apparent Initial Elimination Rate Constant (Lambda [alpha]) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The Lambda (alpha) determined by linear regression of the first elimination phase of the ln-linear plasma concentration-time curve.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Apparent Terminal Elimination Rate Constant (Lambda [z]) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The Lambda (z) determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve.
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Apparent Initial Half-life (t[1/2alpha]) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The t(1/2alpha) is defined as 0.693/Lambda (alpha).
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Apparent Terminal Half-life (t[1/2term]) of ALS 008176, ALS-008206, ALS-008112, and ALS-008144
Time Frame: Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
The t(1/2term) is defined as 0.693/Lambda (z).
|
Pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose
|
Amount of ALS 008176, ALS-008206, ALS-008112, and ALS-008144 excreted in Urine (Ae[x-y])
Time Frame: Up to 48 hours post-dose
|
Amount excreted into urine over a given time interval, calculated from the urinary drug concentration of the collection interval x to y hours post dosing multiplied with the associated urine volume of the interval.
|
Up to 48 hours post-dose
|
Total Amount of ALS 008176, ALS-008206, ALS-008112, and ALS-008144 excreted in Urine (Ae[total])
Time Frame: Up to 48 hours post-dose
|
Total amount excreted into urine, calculated by adding the amounts of the individual intervals together {Ae[0-48hours(h)]}.
|
Up to 48 hours post-dose
|
Total Percentage of ALS 008176, ALS-008206, ALS-008112, and ALS-008144 dose excreted into urine
Time Frame: Up to 48 hours post-dose
|
Total percentage of the dose excreted into urine, calculated as 100 * (Ae[total]/Dose).
|
Up to 48 hours post-dose
|
Renal clearance
Time Frame: Up to 48 hours post-dose
|
Renal clearance calculated as Ae (0-48h)/AUC (0-48h).
|
Up to 48 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Screening up to follow-up (14 days after dose administration)
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Screening up to follow-up (14 days after dose administration)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (ACTUAL)
July 1, 2015
Study Completion (ACTUAL)
July 1, 2015
Study Registration Dates
First Submitted
June 18, 2015
First Submitted That Met QC Criteria
June 18, 2015
First Posted (ESTIMATE)
June 23, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
July 11, 2016
Last Update Submitted That Met QC Criteria
July 7, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR107180
- 64041575RSV1001 (OTHER: Janssen Pharmaceutical K.K., Japan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus Infections
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus ImmunizationPuerto Rico, United States, Australia, Honduras, Mexico
-
EuBiologics Co.,LtdNot yet recruitingRespiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)
-
Clover Biopharmaceuticals AUS Pty LtdRecruitingRespiratory Syncytial Virus InfectionAustralia
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus InfectionUnited States, Puerto Rico
-
PfizerCompletedRespiratory Syncytial Virus InfectionChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedRespiratory Syncytial Virus InfectionHonduras, United States, Chile
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus InfectionJapan
-
Shanghai Ark Biopharmaceutical Co., Ltd.Ark Biosciences Pty Ltd.CompletedRESPIRATORY SYNCYTIAL VIRUS INFECTIONSAustralia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Clinical Trials on ALS-008176 (250 mg)
-
Janssen Research & Development, LLCCompleted
-
Alios Biopharma Inc.CompletedRespiratory Syncytial Virus InfectionsUnited Kingdom
-
Alios Biopharma Inc.CompletedRespiratory Syncytial Virus InfectionsFrance
-
Alios Biopharma Inc.CompletedRespiratory Syncytial Virus InfectionsUnited States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
-
Alios Biopharma Inc.CompletedRespiratory Syncytial Virus InfectionsAustralia, Singapore, United States, New Zealand, Taiwan
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Alios Biopharma Inc.CompletedRespiratory Syncytial Virus InfectionsUnited Kingdom
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCTerminatedRespiratory Syncytial VirusesUnited States, Belgium, Canada, Hungary, Japan, Poland
-
Janssen Research & Development, LLCWithdrawnMetapneumovirusNetherlands, United States, France, Taiwan, Korea, Republic of, Australia, Japan, Spain, Malaysia, Russian Federation, Sweden, Poland, Bulgaria, Argentina, Brazil, Ukraine